IP Verse

Novartis Pharma competitive analysis

Latest oppositions filed by Novartis Pharma

Explore patent oppositions filed by Novartis Pharma against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 17, 2026
Patent NumberTitleApplicantOpposition Date
EP2710355
Method Of Detecting Polymorphs Using Synchrotron RadiationZACH SYSTEMApr 27, 2017
EP2055313
Treatment Of Hematologic Malignancies Associated With Circulating Tumor Cells Using Chimeric Anti-Cd20 AntibodyBIOGENJan 29, 2016

Latest patents of Novartis Pharma opposed by its competitors

Explore Novartis Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 17, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP4218732
Mar 26, 2025Tablets Comprising Eltrombopag Olamine3
EP3143995
Jan 15, 2025A Rapamycin Derivative For Treating Lung Cancer7
EP3090730
Jul 3, 2024Novel Pharmaceutical Composition7
EP2784084
Oct 4, 2023Il-17 A/F Heterologous Polypeptides And Therapeutics Uses Thereof6
EP3345602
Apr 6, 2022Rapamycin Derivative For Treating Advanced Solid Tumours3
EP3003316
Jul 22, 2020Combination Therapies For Cancer1
EP2340828
Jul 15, 2020Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor8
EP2228064
Dec 11, 2019Pharmaceutical Composition Containing Glycopyrrolate And A Beta2 Adrenoceptor Agonist11
EP2284167
Nov 27, 2019Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide1
EP3351246
Sep 18, 2019Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis10

Latest PTAB cases involving Novartis Pharma

Discover the latest PTAB cases involving Novartis Pharma, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 21, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Novartis Pharma

IPR2023-01346Aug 28, 2023NOVARTIS PHARMACEUTICALSTHE REGENTS OF THE UNIVERSITY OF MICHIGANFinal Written Decision - Appealed
IPR2023-01347Aug 28, 2023NOVARTIS PHARMACEUTICALSTHE REGENTS OF THE UNIVERSITY OF MICHIGANTerminated-Adverse Judgment
IPR2022-00886Apr 20, 2022NOVARTIS PHARMACEUTICALSSHILPA PHARMAFinal Written Decision
IPR2022-00853Apr 12, 2022MILTENYI BIOMEDICINENOVARTIS PHARMAInstitution Denied
IPR2021-00816Apr 16, 2021REGENERON PHARMACEUTICALSNOVARTIS PHARMAFinal Written Decision
IPR2020-01263Aug 7, 2020BIOCON PHARMANOVARTIS PHARMACEUTICALSInstitution Denied
IPR2020-01317Jul 16, 2020REGENERON PHARMACEUTICALSNOVARTIS PHARMAInstitution Denied
IPR2020-01318Jul 16, 2020REGENERON PHARMACEUTICALSNOVARTIS PHARMATerminated
IPR2018-01287Jun 18, 2018NOVARTIS PHARMACEUTICALSPLEXXIKONInstitution Denied
PGR2018-00069Jun 18, 2018NOVARTIS PHARMACEUTICALPLEXXIKONInstitution Denied

Peer Comparison New

IP litigation analysis comparing Novartis Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 17, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
NOVARTIS12542 - 21
GENERICS UK319 - - -
STADA ARZNEIMITTEL15429 - -
TEVA PHARMACEUTICAL INDUSTRIES LTD2737 - -